What is the 13F Pro Quality Score for COYA?

13F Pro ranks Coya Therapeutics, Inc. (COYA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View COYA's current score at https://13fpro.ai/research/COYA (free sign-up required for the full ranking).

Where does 13F Pro source COYA data?

All Coya Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Coya Therapeutics, Inc. files with the SEC under CIK 1835022. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is COYA in?

Coya Therapeutics, Inc. (COYA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is COYA research updated on 13F Pro?

COYA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Coya Therapeutics, Inc.(COYA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1835022 COYA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $7.9M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

COYA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Coya Therapeutics, Inc. (COYA), a Healthcare sector company. COYA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $7.9m in revenue. Based on the latest XBRL financial filings (Q1 2026), Coya Therapeutics, Inc. reports quarterly revenue of $251.1K, net income of $-7.2M, free cash flow of $-6.2M. Top institutional holders of COYA by reported 13-F value include DME Capital Management,, AIGH Capital Management, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. COYA trades on the Nasdaq exchange and files with the SEC under CIK 1835022. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COYA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Coya Therapeutics, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$251.1K

Net Income

Q1 2026

$-7.2M

Free Cash Flow

Q1 2026

$-6.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+123.6% YoY

$7.9MFY 2025

FY22 $0.00FY23 $6.0MFY24 $3.6MFY25 $7.9M

Net Income

-42.6% YoY

$-21.2MFY 2025

FY22 $-12.2MFY23 $-8.0MFY24 $-14.9MFY25 $-21.2M

Operating Income

-30.8% YoY

$-22.6MFY 2025

FY22 $-9.8MFY23 $-7.9MFY24 $-17.2MFY25 $-22.6M

EPS (Diluted)

-29.6% YoY

$-1.27FY 2025

FY22 $-4.73FY23 $-0.79FY24 $-0.98FY25 $-1.27

Total Assets

+12.6% YoY

$50.0MFY 2025

FY22 $8.4MFY23 $41.3MFY24 $44.3MFY25 $50.0M

Op. Cash Flow

-4.4% YoY

$-10.7MFY 2025

FY22 $-7.2MFY23 $-11.2MFY24 $-10.3MFY25 $-10.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$7.9M +123.6%	$3.6M -40.8%	$6.0M	$0.00	—	—
Net Income	$-21.2M -42.6%	$-14.9M -86.3%	$-8.0M +34.8%	$-12.2M -150.3%	$-4.9M	—
Operating Income	$-22.6M -30.8%	$-17.2M -118.3%	$-7.9M +19.5%	$-9.8M -101.5%	$-4.9M	—
EPS (Diluted)	$-1.27 -29.6%	$-0.98 -24.1%	$-0.79 +83.3%	$-4.73 -150.3%	$-1.89	—
Total Assets	$50.0M +12.6%	$44.3M +7.5%	$41.3M +391.5%	$8.4M +75.2%	$4.8M	—
Operating Cash Flow	$-10.7M -4.4%	$-10.3M +8.0%	$-11.2M -54.6%	$-7.2M -85.5%	$-3.9M	—

AI Insight: COYA Financial Trends

Pre-revenue biotech burning cash with volatile quarterly results; Q3 2025 showed brief operational improvement before deteriorating again.

• Revenue appeared in Q3 and Q4 2025 ($4M each), then reverted to $0M in Q1 2026—unclear if sustainable product sales or milestone payments.

• Operating cash burn improved to -$1M in Q4 2025, but deteriorated to -$6M in Q1 2026—highest quarterly burn in the dataset.

• Equity swung from $27M nadir (Q3 2025) to $49M (Q1 2026)—likely capital raise masking underlying cash consumption.

⚠ Operating losses averaged -$5.5M per quarter through Q1 2026 with no clear path to profitability; runway depletion risk material.

⚠ Q3 2025 net loss of -$2M was best in dataset, but net loss widened back to -$7M in Q1 2026—improvement was not sustained.

AI Insight: COYA Ratio Trends

Coya remains deeply unprofitable with deteriorating returns; Q4 2025 marked the worst quarter on record across all profitability metrics.

• Operating margin collapsed to -152.3% in Q4 2025, worst quarter since Q2 2024's -94.5%; TTM OpMargin now -68.3%.

• ROIC declined to -62.4% in Q1 2026 from -35.7% in Q3 2025, a 27pp deterioration in just two quarters.

• Q3 2025 showed brief margin improvement (OpMargin -68.3%, NPM -59.4%), but gains reversed sharply in Q4 2025.

⚠ Q4 2025 appears to be an outlier with -152.3% OpMargin; investigate one-time charges or operational breakdowns.

⚠ No leverage data available; assess whether debt is increasing to fund operating losses.

Get alerted when COYA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Coya Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of COYA

DME Capital Management, LP
$9.2M2,335,540 sh
AIGH Capital Management LLC
$3.8M975,404 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.3M844,913 sh
Alyeska Investment Group, L.P.
$3.2M800,000 sh
Prosight Management, LP
$1.7M420,360 sh
CM Management, LLC
$1.5M375,000 sh
PRIVATE MANAGEMENT GROUP INC
$1.5M369,096 sh
GEODE CAPITAL MANAGEMENT, LLC
$919.8K233,402 sh
MARSHALL WACE, LLP
$889.6K225,792 sh
VANGUARD FIDUCIARY TRUST CO
$551.2K139,886 sh

Fund	Value	Shares
DME Capital Management, LP	$9.2M	2,335,540
AIGH Capital Management LLC	$3.8M	975,404
VANGUARD CAPITAL MANAGEMENT LLC	$3.3M	844,913
Alyeska Investment Group, L.P.	$3.2M	800,000
Prosight Management, LP	$1.7M	420,360
CM Management, LLC	$1.5M	375,000
PRIVATE MANAGEMENT GROUP INC	$1.5M	369,096
GEODE CAPITAL MANAGEMENT, LLC	$919.8K	233,402
MARSHALL WACE, LLP	$889.6K	225,792
VANGUARD FIDUCIARY TRUST CO	$551.2K	139,886

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put COYA on your watchlist

Track score changes the day Coya Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is COYA a good stock to buy?

13F Pro's AI-powered analysis of Coya Therapeutics, Inc. (COYA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for COYA are available on the COYA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own COYA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling COYA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Coya Therapeutics, Inc.'s investment landscape.